1 not yet recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
Follow abrysvo: new trials by email Literature Review of abrysvo trials Research Report on abrysvo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women MKK900 60 µg, MKK900 120 µg, ABRYSVO® - Respiratory Syncytial Virus (RSV) | Phase 1 | Not yet recruiting | MAXVAX Biotechnology Limited Liability Company | 120 | 2026-04-01 | 2026-03-25 |
MAXVAX Biotechnology Limited Liability Company (1)
Australia (1)